Consensus $22.40. Backs FY25 revenue view $58B-$61B, consensus $59.57B. Sees FY25 tax rate 17%. The company said, “Guidance for EPS for 2025 decreased to the range of $20.17 to $21.67 on a reported basis, driven by the acquired IPR&D charges and net losses on investments in equity securities and $20.78 to $22.28 on a non-GAAP basis, driven by the acquired IPR&D charges. The company’s updated 2025 financial guidance reflects adjustments shown in the reconciliation table below.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Options Volatility and Implied Earnings Moves Today, May 01, 2025
- Is Eli Lilly’s $850 Billion Valuation Too Expensive Ahead of Earnings?
- Notable companies reporting before tomorrow’s open
- WW International Stock (WW) Doubles on Eli Lilly Weight-Loss Drug Partnership
- Creyon Bio receives $13M upfront in collaboration with Eli Lilly